Last reviewed · How we verify
Filgrastim SD/01
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the production and release of neutrophils from bone marrow to increase white blood cell counts.
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the production and release of neutrophils from bone marrow to increase white blood cell counts. Used for Chemotherapy-induced neutropenia in cancer patients, Mobilization of peripheral blood progenitor cells for stem cell transplantation.
At a glance
| Generic name | Filgrastim SD/01 |
|---|---|
| Also known as | G-CSF, Neupogen |
| Sponsor | M.D. Anderson Cancer Center |
| Drug class | Granulocyte colony-stimulating factor (G-CSF) |
| Target | G-CSF receptor (GCSFR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Filgrastim binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and activation. This results in increased neutrophil production and mobilization into peripheral blood, helping to prevent or reduce the severity of chemotherapy-induced neutropenia and its associated infections.
Approved indications
- Chemotherapy-induced neutropenia in cancer patients
- Mobilization of peripheral blood progenitor cells for stem cell transplantation
Common side effects
- Bone pain
- Headache
- Fatigue
- Injection site reactions
- Splenomegaly
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
- Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (PHASE2)
- Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (PHASE2)
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Filgrastim SD/01 CI brief — competitive landscape report
- Filgrastim SD/01 updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI